NasdaqGM - Nasdaq Real Time Price USD

Xenon Pharmaceuticals Inc. (XENE)

Compare
38.47 -1.38 (-3.46%)
At close: September 6 at 4:00 PM EDT
37.50 -0.97 (-2.52%)
After hours: September 6 at 7:10 PM EDT
Loading Chart for XENE
DELL
  • Previous Close 39.85
  • Open 39.71
  • Bid 38.44 x 200
  • Ask 38.61 x 100
  • Day's Range 38.47 - 40.03
  • 52 Week Range 27.99 - 50.99
  • Volume 260,289
  • Avg. Volume 402,409
  • Market Cap (intraday) 2.915B
  • Beta (5Y Monthly) 1.25
  • PE Ratio (TTM) --
  • EPS (TTM) -2.73
  • Earnings Date Nov 6, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 57.65

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

www.xenon-pharma.com

251

Full Time Employees

December 31

Fiscal Year Ends

Recent News: XENE

View More

Performance Overview: XENE

Trailing total returns as of 9/6/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

XENE
16.48%
S&P 500
13.39%

1-Year Return

XENE
2.14%
S&P 500
20.27%

3-Year Return

XENE
111.37%
S&P 500
19.25%

5-Year Return

XENE
290.96%
S&P 500
81.73%

Compare To: XENE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: XENE

View More

Valuation Measures

Annual
As of 9/6/2024
  • Market Cap

    2.91B

  • Enterprise Value

    2.20B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    3.45

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -18.92%

  • Return on Equity (ttm)

    -26.71%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -199.06M

  • Diluted EPS (ttm)

    -2.73

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    721.53M

  • Total Debt/Equity (mrq)

    1.19%

  • Levered Free Cash Flow (ttm)

    -104.09M

Research Analysis: XENE

View More

Company Insights: XENE

Research Reports: XENE

View More

People Also Watch